Hep B biotech Antios closed after FDA hold proved insurmountable

Viral disease biotech Antios Therapeutics shut down earlier this year after an FDA hold on its lead hepatitis B therapy due to a serious adverse event proved insurmountable. | Viral disease biotech Antios Therapeutics shut down earlier this year after an FDA hold on its lead hepatitis B therapy due to a serious adverse event proved insurmountable.

Former J&J R&D chief Mathai Mammen lands at FogPharma

Annalee Armstrong - Journalist Profile - Intelligent Relations

Annalee Armstrong - Journalist Profile - Intelligent Relations

Antios Therapeutics' ATI-2173 Demonstrates Suppression of

Former J&J R&D chief Mathai Mammen lands at FogPharma

Journal of Medicinal Chemistry

Landon Loving sur LinkedIn : GSK's $100M ADC bet in doubt after

Microfluidic Formulation of Topological Hydrogels for Microtissue

Frontiers Toward a Functional Cure for Hepatitis B: The

Hepatitis B Foundation

Hepatitis B drug developers chart slow progress, just like in hep C

Frontiers Presumed Protective Role for Anti-Hepatitis B Virus